Depressive Disorder News and Research

RSS

Study elaborates relationship between obesity and MDD-R, long-term use of ADs

This study demonstrates that patients using antidepressants continuously, mostly serotonin-selective reuptake inhibitors, show significantly more overweight and obesity than those using them intermittently or not at all.

18 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Researchers present new findings on role of relationship between patient and therapist

This study published in the last 2010 issue of Psychotherapy and Psychosomatics suggests that therapist and patient ratings of therapeutic alliance predict therapeutic progress.

18 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

Stigma remains over Major Depressive Disorder

Despite there being 39.1 million people suffering from major depressive disorder (MDD) across the seven major markets, only one third of patients will seek help from a physician, finds latest research from independent analyst Datamonitor.

11 Jan 2011

Bright light therapy for the aged depressed: Study

A new study shows that exposure to bright light may ease symptoms of depression in elderly people. The researchers tried three weeks of bright light therapy using specially designed light boxes and saw that it improved symptoms of depression by as much as 54% in older adults with depression. The light therapy also improved sleep and optimized levels of the neurotransmitter serotonin. Low levels of serotonin are associated with depression and often targeted by antidepressant drugs. This is the first study of its kind to show a beneficial effect of bright light therapy on treating depression in the elderly with non-seasonal major depressive disorder.

5 Jan 2011

Clinical Data closes sale of genetic, pharmacogenomic testing and biomarker development business

Clinical Data, Inc. today announced that the Company has closed the sale of its genetic and pharmacogenomic testing and biomarker development business to Transgenomic, Inc. for $15.5 million. The sale completes Clinical Data's transformation into a pharmaceutical company with a deep product pipeline, including two promising late-stage compounds, the most advanced of which is vilazodone, a new treatment in development for Major Depressive Disorder.

30 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Psychotic depression: the reason for treatment failure with antidepressants

A new study shows that patients with depression who also have psychotic-like symptoms, feelings of being persecuted, or believing others are plotting against them or hearing voices are less likely to respond to antidepressants. The study also showed that bipolar disorder does not appear to be associated with treatment resistance in patients with depression as believed earlier.

7 Dec 2010

Study finds duplicated region of DNA in major depressive disorder

A large genetic study of people with major depression has found that a duplicated region of DNA on chromosome 5 predisposes people to the disorder. The gene involved plays an important role in the development of nerve cells, adding to evidence that disruptions in neurotransmission networks form a biological basis for depression.

1 Dec 2010

Use of aspirin and statins can reduce depression: Study

A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.

25 Nov 2010

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

24 Nov 2010

FDA warning leads to decrease in antidepressant prescribing for young patients

An FDA warning regarding increased suicide risk in children and teens taking antidepressant drugs has led to an overall decrease in antidepressant prescribing for young patients, reports a study in the November issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

24 Nov 2010

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.

22 Nov 2010

Ridge announces data from Clinical Experience Program on blood test for MDD disorder

Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from a Clinical Experience Program for its first-in-class, proprietary blood test for Major Depressive Disorder (MDD) will be presented during a poster session entitled Clinician Acceptance and Utility of a Multianalyte Biomarker Panel for Major Depressive Disorder (MDD) Diagnosis.

19 Nov 2010

Clinical Data receives U.S. patent for vilazodone

Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.

16 Nov 2010

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Cognitive symptoms of depression cannot be simply discarded as risk factors for heart disease progression. When using a structured diagnostic interview, both somatic and cognitive symptoms of depression are associated with adverse cardiac outcome after adjusting for potential confounders.

11 Nov 2010

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.

8 Nov 2010